Primary resistance, where the best response achieved is progressive disease, is a relatively rare occurrence, and is noted in 4–10% of EGFR mutation-positive NSCLC treated with an EGFR TKI [30,32,33,34,36,39,40,41,43,45]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.